AU684578B2 - Antagonists to chaperonin 10 - Google Patents

Antagonists to chaperonin 10 Download PDF

Info

Publication number
AU684578B2
AU684578B2 AU11036/95A AU1103695A AU684578B2 AU 684578 B2 AU684578 B2 AU 684578B2 AU 11036/95 A AU11036/95 A AU 11036/95A AU 1103695 A AU1103695 A AU 1103695A AU 684578 B2 AU684578 B2 AU 684578B2
Authority
AU
Australia
Prior art keywords
epf
antibodies
peptide
cpnl0
agqafrkflpl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU11036/95A
Other languages
English (en)
Other versions
AU1103695A (en
Inventor
Alice Christina Cavanagh
Halle Morton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8234A external-priority patent/AUPM823494A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of AU1103695A publication Critical patent/AU1103695A/en
Application granted granted Critical
Publication of AU684578B2 publication Critical patent/AU684578B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
AU11036/95A 1993-11-30 1994-11-30 Antagonists to chaperonin 10 Ceased AU684578B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPM2705 1993-11-30
AUPM270593 1993-11-30
AUPM8234 1994-09-16
AUPM8234A AUPM823494A0 (en) 1994-09-16 1994-09-16 Diagnostic and therapeutic uses of chaperonin 10
PCT/AU1994/000742 WO1995015339A1 (en) 1993-11-30 1994-11-30 Antagonists to chaperonin 10

Publications (2)

Publication Number Publication Date
AU1103695A AU1103695A (en) 1995-06-19
AU684578B2 true AU684578B2 (en) 1997-12-18

Family

ID=25644587

Family Applications (2)

Application Number Title Priority Date Filing Date
AU11036/95A Ceased AU684578B2 (en) 1993-11-30 1994-11-30 Antagonists to chaperonin 10
AU11034/95A Ceased AU684577B2 (en) 1993-11-30 1994-11-30 Chaperonin 10

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU11034/95A Ceased AU684577B2 (en) 1993-11-30 1994-11-30 Chaperonin 10

Country Status (11)

Country Link
US (3) US6113899A (https=)
EP (2) EP0733071A4 (https=)
JP (3) JP3545408B2 (https=)
AT (1) ATE282634T1 (https=)
AU (2) AU684578B2 (https=)
CA (1) CA2177179C (https=)
DE (1) DE69434137T2 (https=)
ES (1) ES2233938T3 (https=)
NZ (2) NZ276670A (https=)
PT (1) PT731811E (https=)
WO (2) WO1995015339A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT731811E (pt) * 1993-11-30 2005-04-29 Univ Queensland Chaperonina 10
JP2001509396A (ja) * 1997-07-10 2001-07-24 メディカル リサーチ カウンシル シャペロン断片
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
CN100406891C (zh) * 2001-06-27 2008-07-30 詹森药业有限公司 利用EPF受体鉴定结合或调节hDRR活性的化合物以及hDRR的分离
AU2002952492A0 (en) 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US20070275890A1 (en) * 2004-01-16 2007-11-29 Johnson Barbara J Chaperonin 10 Modulation Of Toll-Like Receptor-Inducible Cytokine And Chemokine Secretion
CN101309934B (zh) 2005-08-31 2014-02-12 悉生物有限公司 修饰的伴侣蛋白10
JP2009511610A (ja) * 2005-10-20 2009-03-19 シービーアイオー リミテッド 過敏症治療
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
MX2008011167A (es) * 2006-03-02 2008-11-12 Cbio Ltd Regulaciòn de respuestas inmunes mediante la modulaciòn de la funciòn de cèlulas presentadoras de antìgenos.
CA2720617A1 (en) 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
MX2012004067A (es) * 2009-10-09 2012-08-03 Cbio Ltd Variantes de la chaperonina 10.
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
KR101776013B1 (ko) * 2017-05-26 2017-09-07 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질 10과 브라제인 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5589786A (en) * 1985-03-12 1986-10-13 University Of Queensland, The Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
AU1086988A (en) * 1986-12-22 1988-07-15 University Of Queensland, The Method of treatment of mammals using antibodies to early pregnancy factor (epf)
AU1103495A (en) * 1993-11-30 1995-06-19 University Of Queensland, The Chaperonin 10

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2192634B (en) * 1985-03-12 1990-03-21 Univ Queensland Method of detecting early pregnancy factor (epf) in mammals, purifying epf and method for providing a monoclonal antibody
EP0345260A4 (en) * 1986-12-22 1990-05-14 Univ Queensland METHOD FOR TREATING MAMMALS WITH ANTIBODIES AGAINST THE EARLY RECEPTION FACTOR (EPF).

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5589786A (en) * 1985-03-12 1986-10-13 University Of Queensland, The Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
AU1086988A (en) * 1986-12-22 1988-07-15 University Of Queensland, The Method of treatment of mammals using antibodies to early pregnancy factor (epf)
AU1103495A (en) * 1993-11-30 1995-06-19 University Of Queensland, The Chaperonin 10

Also Published As

Publication number Publication date
JP3986481B2 (ja) 2007-10-03
AU1103495A (en) 1995-06-19
US7358329B2 (en) 2008-04-15
JP3545408B2 (ja) 2004-07-21
CA2177179A1 (en) 1995-06-08
ATE282634T1 (de) 2004-12-15
EP0731811B1 (en) 2004-11-17
WO1995015339A1 (en) 1995-06-08
EP0733071A4 (en) 1997-02-26
AU684577B2 (en) 1997-12-18
CA2177179C (en) 2006-10-17
AU1103695A (en) 1995-06-19
DE69434137D1 (en) 2004-12-23
ES2233938T3 (es) 2005-06-16
JPH09505811A (ja) 1997-06-10
US20030175280A1 (en) 2003-09-18
EP0731811A1 (en) 1996-09-18
DE69434137T2 (de) 2005-12-01
JP3987104B2 (ja) 2007-10-03
EP0733071A1 (en) 1996-09-25
JPH09506431A (ja) 1997-06-24
NZ276670A (en) 1998-01-26
WO1995015338A1 (en) 1995-06-08
PT731811E (pt) 2005-04-29
NZ276672A (en) 1998-01-26
US6417334B1 (en) 2002-07-09
US6113899A (en) 2000-09-05
JP2004067698A (ja) 2004-03-04
EP0731811A4 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
AU684578B2 (en) Antagonists to chaperonin 10
Cavanagh et al. The purification of early‐pregnancy factor to homogeneity from human platelets and identification as chaperonin 10
Senger et al. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin
Kummer et al. Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins
JPH03197499A (ja) 腫瘍壊死因子結合蛋白
Husby et al. Amyloid fibril protein subunit,‘protein AS’: distribution in tissue and serum in different clinical types of amyloidosis including that associated with myelomatosis and Waldenström's macroglobulinaemia
Cavanagh Production in vitro of mouse early pregnancy factor and purification to homogeneity
JP2980334B2 (ja) ラットの顎下腺から導出したペプチド及びポリペプチド、対応するポリクローナル及びモノクローナル抗体、対応するハイブリドーマ並びに診断、検出及び治療目的でのこれらの生成物の使用
IBRAHIM et al. Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
JPH0356499A (ja) 新規なサイトカイン
Goodfellow et al. Monoclonal antibodies reacting with murine teratocarcinoma cells.
US6117421A (en) Method for promoting cell growth and immunosuppression using chaperonin
Hayashi et al. Efficient production of recombinant cystatin C using a peptide-tag, 4AaCter, that facilitates formation of insoluble protein inclusion bodies in Escherichia coli
JPH04505614A (ja) タンパク質複合体
Curran et al. Isolation and partial characterization of the amino-terminal propeptide of type II procollagen from chick embryos
Bolton et al. Goodpasture's epitope in development of experimental autoimmune glomerulonephritis in rats
JPH1070986A (ja) ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
Groves et al. β2-Microglobulin and its relationship to the immune system
Evans et al. Identification of a vimentin‐like function associated molecule (FAM) on rat NK cells: evidence for receptor function
Pleau et al. [19] Thymulin
Tokuyama et al. Separation and comparison of human TL-like antigens and HLA (A, B, C) antigens expressed on cultured T cells
US4578219A (en) Antigenic peptide compound
JPH06125784A (ja) モノクローナル抗体，ハイブリドーマ，その製造法および用途
Morrow The structure-function relationship of glucose-dependent insulinotropic polypeptide
Pizzonia Cell biology of the Tamm-Horsfall glycoprotein